{"id":40909,"date":"2024-07-04T15:15:02","date_gmt":"2024-07-04T13:15:02","guid":{"rendered":"https:\/\/www.maiwald.eu\/?post_type=publikationen&#038;p=40909"},"modified":"2024-07-04T15:19:45","modified_gmt":"2024-07-04T13:19:45","slug":"is-the-medical-use-disclosure-standard-different-for-novelty-and-sufficiency-managing-ip-2024","status":"publish","type":"publikationen","link":"https:\/\/www.maiwald.eu\/de\/publikationen\/is-the-medical-use-disclosure-standard-different-for-novelty-and-sufficiency-managing-ip-2024\/","title":{"rendered":"Is the medical use disclosure standard different for novelty and sufficiency?, Managing IP, 2024"},"content":{"rendered":"\n<p><a href=\"https:\/\/www.maiwald.eu\/de\/team\/eva-ehlich\/\">Eva Ehlich<\/a> und <a href=\"https:\/\/www.maiwald.eu\/de\/team\/anja-fux\/\">Anja Fux<\/a> von Maiwald er\u00f6rtern eine Entscheidung der EPA-Kammer zum Offenbarungsstandard hinsichtlich der Neuheit und der hinreichenden therapeutischen Wirkung im Kontext der bestehenden Rechtsprechung.<\/p>\n","protected":false},"template":"","meta":{"_acf_changed":false,"footnotes":""},"class_list":["post-40909","publikationen","type-publikationen","status-publish","hentry"],"acf":[],"_links":{"self":[{"href":"https:\/\/www.maiwald.eu\/de\/wp-json\/wp\/v2\/publikationen\/40909","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.maiwald.eu\/de\/wp-json\/wp\/v2\/publikationen"}],"about":[{"href":"https:\/\/www.maiwald.eu\/de\/wp-json\/wp\/v2\/types\/publikationen"}],"version-history":[{"count":3,"href":"https:\/\/www.maiwald.eu\/de\/wp-json\/wp\/v2\/publikationen\/40909\/revisions"}],"predecessor-version":[{"id":40920,"href":"https:\/\/www.maiwald.eu\/de\/wp-json\/wp\/v2\/publikationen\/40909\/revisions\/40920"}],"wp:attachment":[{"href":"https:\/\/www.maiwald.eu\/de\/wp-json\/wp\/v2\/media?parent=40909"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}